IGXT (Mcap $29 M) 1x Drug launched + 2x NDA filings in 1Q13 + Profitable in 2013 = 10 BAGGER EASILY !!!
THIS UNKNOWN GEM IS DEFINITELY THE CHEAPEST STOCK IN THE BIOTECH SECTOR .PLEASE DO YOUR OWN DD AND REALIZE THE MONSTER POTENTIAL GLTA
Intelgenx launched their first drug Forfivo in October this will push this unknown Gem into Profitability by mid 2013 because of its very low burn-rate of only $1.2 Mil a year !
2x New NDA filings for Migraine and Erectile Dysfunction indication in early 2013 . This Goldmine has 9x Drugs in their Mega Pipeline which will be all on the Market within next 2-3 years .
IGXT has NO DEBT and current Market cap of only $29 M is really a BIG BIG BARGAIN .
My Target is $8-12 within 2 Years .GLTA
Market Cap : $ 29 M
Cash: $ 3 M ( Burn-rate only $1.2 M a year )
Price : 0.59 $
Shares Out : 50 M ( 26 M shares are held by Insiders + Institutions)
"We are very excited that our first FDA-approved product, Forfivo XL(TM), has been launched in the USA in early October by our partner Edgemont Pharmaceuticals. We believe that ForFivo XL(TM), as the only single tablet 450mg bupropion HCl available in the U.S., will be a valuable tool for physicians in their management of patients with major depressive disorders," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx. "In addition, following the positive pivotal bioequivalence results announced last quarter for our anti-migraine VersaFilm product, we are pleased to confirm that a recent pre-NDA meeting with FDA confirmed that we remain on track to file our 505(b)(2) NDA submission in the first quarter of 2013.
■ Forfivo™ . The firm's first marketed product,
the high-dose antidepressant agent Forfivo™, is being launched by
IntelGenx's specialty sales partner, Edgemont Pharmaceuticals. A
formal announcement of the commercial availability of Forfivo™ is
expected early next week. In anticipation of the launch of this drug,
which we expect to trigger additional milestone payments to IntelGenx
totaling up to $4mm, we reiterate our Buy rating on IGXT shares.
We are also raising our 18-month price target from $2.50 to $3.00
per share, reflecting both our enthusiasm for the Forfivo™ launch and
in reflection of recent warrant expirations, which have reduced our
projected fully-diluted share count.
■ Buprenorphine / THC Combo Product To Star In 2013. We
believe that IntelGenx's proprietary buprenorphine / THC combination
product, which melds the painkiller buprenorphine with the active
agent in #$%$, tetrahydrocannabinol (THC), could be a substantial
new product for the firm. Unlike the majority of IntelGenx's other
drug candidates, the buprenorphine / THC combo is a novel product
that does not have any direct replicate in the pharmaceutical industry.
IntelGenx has demonstrated in animal models that there is a significant
synergistic effect on pain when buprenorphine and THC are combined
in its product, when compared to buprenorphine or THC alone. In
our view, the applications for this product candidate are varied and
commercially attractive, spanning breakthrough cancer pain, postoperative
pain and chronic pain indications.
■ Solid Financial Footing. IntelGenx closed the second quarter of 2012
with cash of $3.1mm on hand, a decrease of $0.4mm from the end of
2011 and slightly below the cash position of $3.2mm reported at the
end of June 2011. This illustrates the firm's low burn rate. We expect
the firm to close 2012 with roughly $2.5mm in cash.
■ Par Project Partnership Advancing. While IntelGenx has yet to
disclose which candidates it is developing with Par Pharmaceutical Co.
Inc., the progress of these candidates continues. We believe that over
the course of 2013, Par and IntelGenx could disclose the identities of
these agents and the timing with which they might reach the market.